Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Appointed director
CC transcript
|
|
SPECIAL DIVERSIFIED OPPORTUNITIES INC. (SDOIA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/08/2019 |
8-K
| Quarterly results |
| 05/08/2019 |
8-K
| Quarterly results|
Docs:
|
"Consolidated Statements of Income Three Months Ended March 31, 2019 2018 Revenues: Net sales $ 92,309 $ 74,348 Insurance premiums earned 7,149 7,317 Net investment income 335 194 Other income 219 207 Total revenues 100,012 82,066 Operating costs and expenses: Cost of sales 51,784 42,456 Selling, general and administrative expenses 30,733 23,470 Incurred losses and loss adjustment expenses 6,564 5,812 Impairment loss on goodwill and other intangible assets 2,826 - Other operating expenses 2,716 1,289 Total operating costs and expenses 94,623 73,027 Operating income 5,389 9,039 Interest expense 4,491 3,992 Interest and investment income Loss on extinguishment of debt - 2,384 Net periodic benefit income, excluding service cost Income before income taxes 1,071 2,809 Income tax expense 1,354..." |
|
| 03/11/2019 |
8-K
| Quarterly results |
| 11/09/2018 |
8-K
| Quarterly results|
Docs:
|
"Consolidated Statements of Income Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Revenues: Net sales $ 84,035 $ 73,352 $ 240,156 $ 212,226 Insurance premiums earned 7,088 - 21,539 - Net investment income 309 - 679 - Other income 163 - 557 - Total revenues 91,595 73,352 262,931 212,226 Operating costs and expenses: Cost of sales 47,742 40,386 136,147 119,522 Selling, general and administrative expenses 24,492 19,606 70,237 55,355 Incurred losses and loss adjustment expenses 5,790 - 17,007 - Other operating expenses 2,682 - 5,512 - Total operating costs and expenses 80,706 59,992 228,903 174,877 Operating income 10,889 13,360 34,028 37,349 Interest expense 4,450 4,023 12,556 13,002 Interest and investment income Loss on extinguishment of debt - - 2,384..." |
|
| 05/14/2018 |
8-K
| Quarterly results |
| 08/08/2012 |
8-K
| Quarterly results |
| 05/10/2012 |
8-K
| Quarterly results|
Docs:
|
"SDIX Reports First Quarter 2012 Results and First Advanced Genomic Antibody Technology Collaboration with a Major Pharmaceutical Company Conference Call to Review at 4:30PM ET Today NEWARK, DE - SDIX , a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology, diagnostic and food safety applications, today reported financial results for the quarter ended March 31, 2012. Revenue for the first quarter of 2012 was $5.6 million, decreasing from $6.6 million for the same period in 2011. This decrease was primarily related to the timing of IVD sales, a softening biopharmaceutical market, and external regulatory changes in the food industry. Net loss for the first quarter of 2012 was $1.2 million, compared to a net loss of $658,000 for the sa..." |
|
| 03/22/2012 |
8-K
| Form 8-K - Current report |
| 11/14/2011 |
8-K
| Quarterly results |
| 07/28/2011 |
8-K
| Form 8-K - Current report |
| 05/12/2011 |
8-K
| Quarterly results|
Docs:
|
"SDIX Reports First Quarter 2011 Results First Quarter Revenues Increase 12% Year-over-Year Life Science & Food Safety Revenues Increase 19% & 28% Year-over-Year, Respectively NEWARK, DE - SDIX , a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology, diagnostic and food safety applications, today reported financial results for the quarter ended March 31, 2011. Revenues for the first quarter of 2011 were $7.5 million, increasing 12% from $6.7 million for the same period in 2010. This growth was driven by strong revenues in SDIX’s core focus areas of Life Science, up 19%, and Food Safety, up 28%. Net loss for the first quarter of 2011 was $658,000, compared to a net loss of $459,000 in 2010. This increase in net loss was primarily att..." |
|
| 03/03/2011 |
8-K
| Quarterly results |
| 11/08/2010 |
8-K
| Form 8-K - Current report |
| 08/04/2010 |
8-K
| Form 8-K - Current report |
| 02/25/2010 |
8-K
| Form 8-K - Current report |
| 10/29/2009 |
8-K
| Form 8-K - Current report |
| 08/12/2009 |
8-K/A
| Form 8-K/A -- Current report [amend] |
| 05/05/2009 |
8-K
| Form 8-K -- Current report |
| 10/31/2008 |
8-K
| Quarterly results |
| 08/04/2008 |
8-K
| Quarterly results |
| 05/02/2008 |
8-K
| Quarterly results |
| 03/03/2008 |
8-K
| Quarterly results |
| 11/14/2007 |
8-K
| Quarterly results |
| 03/02/2007 |
8-K
| Quarterly results |
| 05/04/2006 |
8-K
| Quarterly results|
Docs:
|
"Strategic Diagnostics Reports First Quarter 2006 Results Overall Revenues Decrease 6.1% While Food Pathogen Sales Increase 55.4% NEWARK, Del., May 4, 2006- Strategic Diagnostics Inc. - a leading provider of biotechnology-based detection solutions for a broad range of food, water, agricultural, industrial, environmental and scientific applications, today reported financial results for the first quarter ended March 31, 2006. Revenues for the first quarter of 2006 decreased 6.1% to $6.3 million, compared to $6.7 million for the same period in 2005. Revenues of the Company’s products for the detection of food pathogens continued to grow significantly in the first quarter of 2006, and were up 55.4% compared to the same quarter in 2005. The negative impact on revenues in the first quarter of 200..." |
|
| 03/23/2006 |
8-K
| Quarterly results|
Docs:
|
"Strategic Diagnostics Reports Fourth Quarter and Year 2005 Results 2005 Sales Increase 4.8% Food Pathogen Sales Increase 84% in Fourth Quarter and 107% vs. Prior Year NEWARK, Del., March 23, 2006 - Strategic Diagnostics Inc. - a leading provider of antibody products and analytical test kits for a broad range of food, water, agricultural, industrial, environmental and scientific applications, today reported financial results for the fourth quarter and year ended December 31, 2005. Revenues for the year ended December 31, 2005 increased 4.8% to $24.85 million, compared to $23.71 million for the same period in 2004. Organic growth delivered a 107.3% increase in revenues from sales of the Company’s products for the detection of food pathogens, and a 5.6% increase in custom antibodies and servi..." |
|
| 11/10/2005 |
8-K
| Quarterly results |
| 05/05/2005 |
8-K
| Quarterly results |
| 03/03/2005 |
8-K
| Quarterly results |
| 11/05/2004 |
8-K
| Quarterly results |
|
|